Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X about a recent article he and colleagues authored:
“Just out in the New England Journal of Medicine!
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance.
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark!
How to test and manage patients. Who needs bone marrow exams and scans? It’s all in here!
MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear, MGCS, MGRS, etc., in this Review.
Shaji Kumar and I have tried to keep every sentence in this Review simple and easy to follow.”
Title: Monoclonal Gammopathy of Undetermined Significance
Authors: Vincent Rajkumar, Shaji Kumar
Read the Full Article in the New England Journal of Medicine.
Raad Chowdhury, Onc nephrologist and Medical Director of OncNph at Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, shared this post, adding:
“I receive quite a bit of consults for MGUS and renal dysfunction. Given the prevalence in the age group, they can coexist without an obvious association. Must read!”
More posts featuring Vincent Rajkumar on OncoDaily.